Prediction of the Outcome for Patients with Glioblastoma with lncRNA Expression Profiles

Abstract

Background. Progress in gene sequencing has paved the way for precise outcome prediction of the heterogeneous disease of glioblastoma. The aim was to assess the potential of utilizing the lncRNA expression profile for predicting glioblastoma patient survival. Materials and Methods. Clinical and lncRNA expression data were downloaded from the public database of the cancer genome atlas. Differentially expressed lncRNAs between glioblastoma and normal brain tissue were screened by bioinformatics analysis. The samples were randomly separated into the training and testing sets. Univariate Cox regression, least absolute shrinkage, selection operator regression, and multivariate Cox regression were performed to develop the prediction model with the training set, which was presented as a forest plot. The performance of the model was validated by discrimination and calibration analysis in both the training and testing sets. Patient survival between model-predicted low- and high-risk subgroups was compared in both the training and testing sets. Results. One thousand two hundred and fifty-five differentially expressed lncRNAs between glioblastoma and normal brain tissues were screened. After univariate Cox regression and the least absolute shrinkage and selection operator regression, a 12 lncRNA constituted prediction model was developed by multivariate Cox regression. Of the 12 lncRNAs, 4 lncRNAs were independent risk factors for patient survival. The areas under the receiver operating characteristic curves of the model for predicting 0.5-, 1-, 1.5-, and 2-year patient survival was 0.788, 0.824, 0.874, and 0.886, respectively in the training set and 0.723, 0.84, 0.816, and 0.773 in the testing set. The calibration curves of the prediction model fitted well. Significant survival disparity was observed between the model dichotomized low- and high-risk subgroups in both the training and testing set. Conclusions. LncRNA expression signature can predict glioblastoma patient survival, promising lncRNA-based survival prediction.

Long Non-Coding RNA UBA6-AS1 Promotes the Malignant Properties of Glioblastoma by Competitively Binding to microRNA-760 and Enhancing Homeobox A2 Expression

“…A large number of lncRNAs are aberrantly expressed in GBM and have been identified as critical regulatory factors in oncogenesis and progression. 26,27 LncRNAs may function as promoters or inhibitors of cancerassociated genes in GBM, and have the ability to modulate the aggressive tumor phenotypes. 28,29 Accordingly, lncRNAs appear to be promising molecular targets for GBM therapy.…”

Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma

“…These provide us the opportunity and resources to explore, integrate and reanalyse the already existing data for new biomarker discovery and validation. In addition, previous studies have reported a correlation between differentially expressed genes (DEGs), microRNAs, long non-coding RNAs and differentially methylated genes and GBM prognosis and have indicated prognostic value using bioinformatic analysis [13][14][15][16][17][18][19][20][21][22][23], but no consistent model exists. For instance, Zuo et al (2019) [15] and Cao et al (2019) [16] identified a panel of 6 and 4 genes, respectively, for prognosis prediction with no genes in common.…”

An In Silico Glioblastoma Microenvironment Model Dissects the Immunological Mechanisms of Resistance to PD‐1 Checkpoint Blockade Immunotherapy

“…[ 35 ] Recently, many computational methods have been developed for guiding the GBM treatments. For example, statistical models integrated with molecular data (such as lncRNA [ 36 ] and microRNA [ 37 ] ) achieved to predict the survival and recurrence time of chemotherapy‐treated GBM patients in an end‐point manner. Some other types of computational models, based on machine learning and image analysis, are able to provide patient‐specific prediction on prognosis.…”